Page 40
A n n u a l S u mm i t o n
Hepatology and Pancreatic
Diseases
November 12-13 , 2018
Par i s , France
Journal of Clinical Gastroenterology and Hepatology
ISSN: 2575-7733
Hepatology and Pancreatic Diseases 2018
Background:
Hepatitis C Virus (HCV) infection is an important health issue and leading cause of chronic liver disease in developing
countries including Pakistan. Therefore, the current study was aimed to assess the treatment responses of available antiviral
regimens.
Methods:
A total of 144 chronic HCV positive patients by real time PCR were enrolled from Department of Gastroenterology,
Pakistan Institute of Medical Sciences (PIMS), Islamabad (North Region), Pakistan. Treatment responses among chronic HCV
positive patients were observed for antiviral regimens. These antiviral regimens were Sofosbuvir + Ribavirin (24 weeks) and
Sofosbuvir + Daclatasvir (12 Weeks). Sofosbuvir (400 mg), (Sovaldi , Gilead Sciences, USA) and Daclatasvir (60 mg ), (MyDekla,
Mylan , USA/Dacklinza, Bristo Myers Squibb, USA) were prescribed to take orally once a day. In addition, Ribavirin (Xolox,
Ferozsons, Pakistan), (400 mg or 600 mg ) had been advised to take orally twice daily on the basis of weight of patients. The end
of treatment response (ETR) after completion of treatment and sustained virological response (SVR) after 12 weeks of cessation
of treatment were assessed by the detection of HCV RNA in sera of treated patients.
Results:
The high ETR and SVR were achieved with Sofosbuvir + Daclatasvir (12 weeks), (92.26%, 71/73) when compared with
Sofosbuvir + Ribavirin (24 weeks), (84.50%, 60/71) among chronic HCV positive patients.
Conclusions:
In conclusion, the 12 weeks HCV antiviral eradication regimen i.e., Sofosbuvir + Daclatasvir was more effective,
economic and a better choice than 24 weeks regimen ‘Sofosbuvir + Ribavirin’ in our region.
ahmedtanveer17@yahoo.com12 Weeks Hepatitis C Virus Antiviral Regimen is
a Better Choice than 24 Weeks Regimen in North
Region of Pakistan
Tanveer Ahmed
1
, Mashhood Ali
1
, Faisal Rasheed
2
1
Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan
2
Pakistan Institute of Nuclear Science and Technology, Pakistan
J Clin Gastroenterol Hepatol 2018, Volume:2
DOI: 10.21767/2575-7733-C3-009




